More Information

Discovery of Verubecestat: A BACE1 Inhibitor in Phase 3 Clinical Development for Alzheimer’s Disease

04
Dec
Dec 4, 2017
4:55 pm
Marillac Auditorium
Open to Public
December 4, 2017 4:55 pm
Add to Calendar

Department of Pharmaceutical Sciences Doctoral Seminars, Fall 2017

Monday, December 4, 2017

Dr. Andrew W. Stamford

Vice President, Chemistry

Tri-Institutional Therapeutics Discovery Institute, New York, NY

Discovery of Verubecestat: A BACE1 Inhibitor in Phase 3 Clinical Development for Alzheimer’s Disease